A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma (NCT07477457)
OstEvo - Osteosarcoma Evolves
🩺 Plain-English Summary (8th-Grade Level)
The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding these drugs to standard chemotherapy. The researchers will also use the additional research biopsies from Cohort 1 participants to learn more about how osteosarcoma survives during chemotherapy.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Age range: 6 Years to 49 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) — Montvale, New Jersey
- Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities) — Uniondale, New York
📞 Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Osteosarcoma
- Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors — New York, New York
- SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma — Los Angeles, California
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma — Birmingham, Alabama
- Olaparib With Ceralasertib in Recurrent Osteosarcoma — San Francisco, California
- A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma — Seattle, Washington
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma — Houston, Texas
Explore by condition: All Osteosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.